Morgan Stanley analyst Sean Laaman lowered the firm’s price target on Argenx (ARGX) to $1,170 from $1,230 and keeps an Overweight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target raised to $1,135 from $1,120 at Guggenheim
- Argenx price target raised to $1,260 from $1,247 at Wells Fargo
- Argenx price target lowered to $1,222 from $1,227 at Stifel
- Argenx Posts 63% Q1 Sales Surge as New CEO Steers Expansion of Autoimmune Portfolio
- Argenx Maintains Buy Rating on Vyvgart Momentum, Robust Profitability, and Expanding Late-Stage Pipeline